jRCT2031240090招募中不适用
Randomized control study of the Efficacy of Radioactive Hypoxia-Targeting Therapeutic Agent 64Cu-ATSM versus standard therapy for Recurrent Malignant Glioma: Investigator Initiated Trial (STEP-64)
未提供0 个研究点目标入组 56 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 56
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 75age old under（—）
- 性别
- All
入选标准
- •Histologically diagnosed as high grade glioma based on WHO2021 criteria (glioblastoma, Grade 3/4 astrocytoma, or Grade 3 oligodendroglioma) before the registration
- •Neither tumor in the cerebellum, brain stem, pituitary gland, optic nerve, olfactory nerve, nor intrathecal dissemination, in both the initial case and recurrence (multiple lesions are eligible).
- •Neither leptomeningeal metastases , nor spinal metastasis requiring radiation therapy or surgical intervention.
- •Aged between 18 and 75 years old
- •KPS (Karnofsky performance status) at the time of registration >= 70
- •Recurrent or residual tumor after the standard therapy as indicated below.
- •(1) local radiation therapy >= 50 Gy
- •(2) TMZ (temozolomide) therapy (150 to 200 mg/m2/day, 5 days oral, 23 days interval) 3 courses or more
- •In a case with a history of radiotherapy, 90 days passed from the last irradiation date at the time of registration
- •No anti-cancer drug treatment (chemotherapy, molecular targeted therapy, immunotherapy, etc.) nor other investigational drugs have been administered within 21 days before registration (the same day of the week for registration is allowed. The criteria listed below are the same)
- •Not underwent surgery with general anesthesia within 14 days before registration
- •As a treatment for tumors other than brain tumor, there is no history of radiotherapy in the head and neck region
- •Patients received laboratory tests within 14 days before registration and fulfilled following criteria:
- •In the case of women of childbearing potential, consent has been granted for contraception for at least 7 weeks after the last dose of study drug. In the case of males, consent to contraception for at least 14 weeks after the start of study drug administration and after the last dose of study drug.
- •Written informed consent
排除标准
- •Have a history or merger of other malignancies within 2 years before registration. Patients with carcinoma in situ or lesions equivalent to intramucosal carcinoma are eligible
- •Have infection requiring systemic treatment at registration
- •Fever of 38C or higher at registration
- •Clinical symptoms or image findings of interstitial pneumonia or pulmonary fibrosis at registration
- •With history of hypersensitivity reaction to contrast agent, claustrophobia, etc. and Gd-enhanced MRI cannot be performed.
- •HIV antibody positive
- •Pregnant or breast-feeding women, or women suspected of being pregnant
- •Mental disease interfering taking part in the trial
结局指标
主要结局
-
overall survival
次要结局
- response rate
- Adverse event expression rate
研究者
相似试验
招募中
不适用
NCCH2213 trial (PLAS trial)jRCT203124044838
招募中
不适用
NCCH2303 trial (CIRCUS trial)jRCT203124021042
招募中
不适用
NCCH2404 trial (SAVE HEART trial)jRCTs03124071955
进行中（未招募）
1 期
Phase 1 trial, HMR code: 21-004The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.Not SpecifiedISRCTN12926361Gedeon Richter Plc104
招募中
不适用
LOGIK2401(NECTAR Study)jRCTs07124005430